AIMS: Endothelial SK(Ca) and IK(Ca) channels play an important role in the regulation of vascular function and systemic blood pressure. Based on our previous findings that small molecule activators of SK(Ca) and IK(Ca) channels (i.e. NS309 and SKA-31) can inhibit myogenic tone in isolated resistance arteries, we hypothesized that this class of compounds may induce effective vasodilation in an intact vascular bed, such as the coronary circulation. METHODS AND RESULTS: In a Langendorff-perfused, beating rat heart preparation, acute bolus administrations of SKA-31 (0.01-5 µg) dose-dependently increased total coronary flow (25-30%) in both male and female hearts; these responses were associated with modest, secondary increases in left ventricular (LV) systolic pressure and heart rate. SKA-31 evoked responses in coronary flow, LV pressure, and heart rate were qualitatively comparable to acute responses evoked by bradykinin (1 µg) and adenosine (10 µg). In the presence of apamin and TRAM-34, selective blockers of SK(Ca) and IK(Ca) channels, respectively, SKA-31 and bradykinin-induced responses were largely inhibited, whereas the adenosine-induced changes were blocked by ∼40%; TRAM-34 alone produced less inhibition. Sodium nitroprusside (SNP, 0.2 μg bolus dose) evoked changes in coronary flow, LV pressure, and heart rate were similar to those induced by SKA-31, but were unaffected by apamin + TRAM-34. The NOS inhibitor L-NNA reduced bradykinin- and adenosine-evoked changes, but did not affect responses to either SKA-31 or SNP. CONCLUSION: Our study demonstrates that SKA-31 can rapidly and reversibly induce dilation of the coronary circulation in intact functioning hearts under basal flow and contractility conditions.
AIMS: Endothelial SK(Ca) and IK(Ca) channels play an important role in the regulation of vascular function and systemic blood pressure. Based on our previous findings that small molecule activators of SK(Ca) and IK(Ca) channels (i.e. NS309 and SKA-31) can inhibit myogenic tone in isolated resistance arteries, we hypothesized that this class of compounds may induce effective vasodilation in an intact vascular bed, such as the coronary circulation. METHODS AND RESULTS: In a Langendorff-perfused, beating rat heart preparation, acute bolus administrations of SKA-31 (0.01-5 µg) dose-dependently increased total coronary flow (25-30%) in both male and female hearts; these responses were associated with modest, secondary increases in left ventricular (LV) systolic pressure and heart rate. SKA-31 evoked responses in coronary flow, LV pressure, and heart rate were qualitatively comparable to acute responses evoked by bradykinin (1 µg) and adenosine (10 µg). In the presence of apamin and TRAM-34, selective blockers of SK(Ca) and IK(Ca) channels, respectively, SKA-31 and bradykinin-induced responses were largely inhibited, whereas the adenosine-induced changes were blocked by ∼40%; TRAM-34 alone produced less inhibition. Sodium nitroprusside (SNP, 0.2 μg bolus dose) evoked changes in coronary flow, LV pressure, and heart rate were similar to those induced by SKA-31, but were unaffected by apamin + TRAM-34. The NOS inhibitor L-NNA reduced bradykinin- and adenosine-evoked changes, but did not affect responses to either SKA-31 or SNP. CONCLUSION: Our study demonstrates that SKA-31 can rapidly and reversibly induce dilation of the coronary circulation in intact functioning hearts under basal flow and contractility conditions.
Authors: Rudi Busse; Gillian Edwards; Michel Félétou; Ingrid Fleming; Paul M Vanhoutte; Arthur H Weston Journal: Trends Pharmacol Sci Date: 2002-08 Impact factor: 14.819
Authors: Rostislav Bychkov; Matthew P Burnham; Gillian R Richards; Gillian Edwards; Arthur H Weston; Michel Félétou; Paul M Vanhoutte Journal: Br J Pharmacol Date: 2002-12 Impact factor: 8.739
Authors: Fu-Xian Yi; Andrew Y Zhang; William B Campbell; Ai-Ping Zou; Cornelis Van Breemen; Pin-Lan Li Journal: Am J Physiol Heart Circ Physiol Date: 2002-08-22 Impact factor: 4.733
Authors: Regis R Lamberts; Mattie H P Van Rijen; Pieter Sipkema; Paul Fransen; Stanislas U Sys; Nico Westerhof Journal: Am J Physiol Heart Circ Physiol Date: 2002-10 Impact factor: 4.733
Authors: Norbert Nagy; Viktória Szuts; Zoltán Horváth; György Seprényi; Attila S Farkas; Károly Acsai; János Prorok; Miklós Bitay; Attila Kun; János Pataricza; Julius Gy Papp; Péter P Nánási; András Varró; András Tóth Journal: J Mol Cell Cardiol Date: 2009-07-24 Impact factor: 5.000
Authors: Cini Mathew John; Rayan Khaddaj Mallat; Ramesh C Mishra; Grace George; Vikrant Singh; Jeannine D Turnbull; Channakeshava S Umeshappa; Dylan J Kendrick; Taeyeob Kim; Fazlin M Fauzi; Frank Visser; Paul W M Fedak; Heike Wulff; Andrew P Braun Journal: Pharmacol Res Date: 2019-11-07 Impact factor: 7.658
Authors: Ramesh C Mishra; Jamie R Mitchell; Carol Gibbons-Kroeker; Heike Wulff; Israel Belenkie; John V Tyberg; Andrew P Braun Journal: Vascul Pharmacol Date: 2015-08-01 Impact factor: 5.773
Authors: Aida Oliván-Viguera; Marta Sofía Valero; Estéfano Pinilla; Sara Amor; Ángel Luis García-Villalón; Nichole Coleman; Celia Laría; Víctor Calvín-Tienza; Ángel-Luis García-Otín; José M Fernández-Fernández; M Divina Murillo; José A Gálvez; María D Díaz-de-Villegas; Ramón Badorrey; Ulf Simonsen; Luis Rivera; Heike Wulff; Ralf Köhler Journal: Basic Clin Pharmacol Toxicol Date: 2016-02-29 Impact factor: 4.080